Abarelix Side Effects: Safety Signals and Warnings
Abarelix safety concerns are compound-specific. The main listed side effects are Immediate-onset allergic reactions (3.7%), Hot flashes, and Sleep disturbances. The main warning signals are Risk of immediate-onset systemic allergic reactions requiring 30-minute post-injection monitoring, Available only through restricted distribution program due to allergy risk, and Bone density loss with prolonged androgen deprivation.
Direct Answer
Abarelix (Plenaxis) is FDA-approved but was withdrawn from the US market due to a 3.7% anaphylaxis rate - a serious safety signal that terminated its commercial development. It established proof-of-concept for GnRH antagonism in prostate cancer, but degarelix (with a superior safety profile and active marketing) has replaced it as the GnRH antagonist of choice. Abarelix is a cautionary example, not a starting point.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Historical GnRH antagonist pharmacology reference only - not recommended for new research protocols
Reported Side Effects
- Immediate-onset allergic reactions (3.7%)
- Hot flashes
- Sleep disturbances
- Breast enlargement
- Pain at injection site
- Constipation
- Peripheral edema
- Fatigue
Warnings
- Risk of immediate-onset systemic allergic reactions requiring 30-minute post-injection monitoring
- Available only through restricted distribution program due to allergy risk
- Bone density loss with prolonged androgen deprivation
- Cardiovascular and metabolic risk profile similar to other ADT
- QT prolongation caution
Known or Plausible Interactions
- QT-prolonging medications (additive cardiac risk with hypogonadism)
- Anticoagulants (intramuscular injection site bleeding risk)
- Other androgen deprivation agents (not typically combined)
Regulatory Context
FDA-approved prescription medication (Plenaxis). Restricted distribution program. Available only in healthcare settings equipped for allergic reaction management. Not a controlled substance. No longer actively marketed in the US.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Rapid Testosterone Suppression (Level A), Prostate Cancer Disease Control (Level A), and Allergic Reaction Risk (Level A) |
| Primary citation count | 2 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Abarelix Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/abarelix-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.